Aligos Therapeutics Inc

10-Year Study

ALGS.US · Healthcare · US · Common Stock

Executive Summary: Aligos Therapeutics Inc has compounded at -50.7% annually over the last 10 years, with a maximum drawdown of 99.3% and an annualized volatility of 189.1%.

1Y CAGR
+49.7%
3Y CAGR
-36.1%
5Y CAGR
-60.0%
10Y CAGR
-50.7%

History & Riski10-year historical performance analysis including CAGR, Max Drawdown, Sharpe & Sortino ratios, annual returns, and rolling volatility — all computed from daily market data.

10-Year Growth of $10,000

Max DrawdownMax DrawdownThe largest peak-to-trough decline in the asset's value over the measurement period.Click for full definition →
99.3%
Sharpe RatioSharpe RatioRisk-adjusted return: how much excess return you earn per unit of total risk (volatility).Click for full definition →
-0.10
Sortino RatioSortino RatioLike Sharpe, but only penalizes downside volatility — a more accurate risk measure for asymmetric return distributions.Click for full definition →
-0.22
Ann. VolatilityAnnualized VolatilityThe annualized standard deviation of an asset's returns — a measure of how much prices fluctuate.Click for full definition →
119.4%
Best YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2024 · +140.0%
Worst YearBest & Worst YearThe single calendar year with the highest and lowest return in the measured period.Click for full definition →
2022 · -92.0%
% Positive Years% Positive YearsThe percentage of calendar years in the measurement period where the asset delivered a positive return.Click for full definition →
17%

Annual Returns

Rolling 12-Month Returns

Rolling 12-Month Annualised Volatility

Historical Drawdowns

Monthly Returns

Monthly Returns Heatmap

YearJanFebMarAprMayJunJulAugSepOctNovDecAnn.
2026-13.4-12.95.73.1————————-17.8%
2025-35.2-34.6-51.1-32.4-5.236.31.044.9-7.1-15.816.1-2.7-76.6%
20243.943.5-1.0-21.9-22.9-40.748.6-2.5-31.712.9160.856.2140.0%
2023103.6-24.7-40.132.7-2.6-14.1-8.3-3.3-13.2-19.716.7-5.1-30.3%
2022-73.1-24.1-11.2-45.19.3-6.22.50.8-12.0-4.5-4.8-4.7-92.0%
20211.92.0-20.913.18.4-26.9-28.517.0-9.02.7-3.8-22.5-57.1%
2020——————————25.247.885.1%

Risk X-RayiA 19-factor macroeconomic risk decomposition showing exactly which market forces (equity beta, rates, inflation, credit, commodity, crypto) drive this asset's volatility. Powered by multivariate regression against daily factor returns.

Risk Profile Insight: This asset has an estimated annualized volatility of 189.1%. The dominant macroeconomic risk driver is VTI.US, accounting for 41.3% of variance. Idiosyncratic stock-specific factors contribute 14.7%.

10-Year Historical Price Series (Growth of $10,000)
DateSimulated Value
2020-10-0110000
2020-11-0112523.427041499332
2020-12-0118507.362784471217
2021-01-0118855.421686746988
2021-02-0119236.947791164657
2021-03-0115220.883534136547
2021-04-0117215.528781793844
2021-05-0118661.31191432396
2021-06-0113644.578313253012
2021-07-019752.342704149933
2021-08-0111412.315930388218
2021-09-0110381.526104417671
2021-10-0110662.650602409638
2021-11-0110254.350736278448
2021-12-017945.113788487282
2022-01-012135.2074966532796
2022-02-011619.8125836680053
2022-03-011439.0896921017404
2022-04-01789.8259705488621
2022-05-01863.4538152610443
2022-06-01809.9062918340027
2022-07-01829.9866131191433
2022-08-01836.6800535475235
2022-09-01736.2784471218206
2022-10-01702.8112449799197
2022-11-01669.3440428380187
2022-12-01637.8848728246318
2023-01-011298.5274431057564
2023-02-01977.2423025435073
2023-03-01585.0066934404284
2023-04-01776.4390896921017
2023-05-01756.3587684069612
2023-06-01649.9330655957161
2023-07-01595.7161981258366
2023-08-01576.3052208835342
2023-09-01500
2023-10-01401.60642570281124
2023-11-01468.5408299866131
2023-12-01444.44444444444446
2024-01-01461.8473895582329
2024-02-01662.6506024096386
2024-03-01655.9571619812583
2024-04-01512.0481927710844
2024-05-01394.91298527443104
2024-06-01234.27041499330656
2024-07-01348.05890227576975
2024-08-01339.49129852744306
2024-09-01231.8607764390897
2024-10-01261.8473895582329
2024-11-01682.9986613119144
2024-12-011066.6666666666667
2025-01-01690.7630522088353
2025-02-01451.67336010709505
2025-03-01220.8835341365462
2025-04-01149.3975903614458
2025-05-01141.63319946452475
2025-06-01193.0388219544846
2025-07-01194.91298527443107
2025-08-01282.4631860776439
2025-09-01262.38286479250337
2025-10-01220.8835341365462
2025-11-01256.49263721552876
2025-12-01249.5314591700134
2026-01-01216.06425702811245
2026-02-01188.21954484605087
2026-03-01198.92904953145916
2026-04-01205.08701472556893
Annual Return Matrix
YearAnnual Return
2021-0.5707052441229656
2022-0.9197135636057288
2023-0.30325288562434405
20241.4
2025-0.7660642570281124
2026-0.17811158798283266
Total Factor Risk
1.891451532622222
VTI.US Exposure
0.41279316518844
VEA.US Exposure
0.0018315841904528044
VWO.US Exposure
-0.004496209875785527
QQQ.US Exposure
-0.0030670841505700507
VTV.US Exposure
0.13493672700238818
IJR.US Exposure
0.06561883346818133
QUAL.US Exposure
0.04082911879897457
SHV.US Exposure
0.03920159132216159
TLT.US Exposure
-0.010064208600531421
LQD.US Exposure
0.14099511576642176
HYG.US Exposure
0.0014844066610803749
GLD.US Exposure
0.001631738611995803
USO.US Exposure
0.000020269362264242715
VNQ.US Exposure
0.002895992175113214
BTC-USD.CC Exposure
0.008389443506837445
CPER.US Exposure
0.002260569153249545
VIX.INDX Exposure
-0.003119068480765649
UUP.US Exposure
0.022581616586841196
TIP.US Exposure
-0.0013279938647740343
Idiosyncratic Exposure
0.14660439317802443
Value Score
50
Growth Score
50
Profit Score
37.5
Health Score
23.6
Yield Score
0
Moat Score
40

Factor Risk Decomposition

Share of annualised volatility attributable to each macro factor.

Total Est. Vol
189.1%

FundamentalsiCompany financial health metrics: P/E valuation, dividend yield, Piotroski F-Score (9-point profitability signal), Altman Z-Score (bankruptcy risk proxy), and a radar chart across 6 fundamental dimensions. Note: ETFs may show N/A for some metrics.

Fundamental Dimensions

Core Valuation

P/E Ratio (TTM)P/E RatioPrice-to-Earnings ratio — the market price of a stock divided by its earnings per share, a key valuation measure.Click for full definition →N/A
Dividend YieldDividend YieldAnnual dividend paid per share divided by the current share price — expressed as a percentage income return.Click for full definition →0.00%
Market Cap$41.8M
Piotroski F-ScorePiotroski F-ScoreA 9-point scoring system evaluating a company's financial strength across profitability, leverage, and operating efficiency.Click for full definition →
9-point profitability signal
0.0/ 9
Weak
Altman Z-ScoreAltman Z-ScoreA bankruptcy prediction model that combines 5 financial ratios into a single score indicating financial distress risk.Click for full definition →
Bankruptcy risk proxy
1.18
Distress Zone
Income Simulation

Based on $10,000 initial investment.

Total Income Generated
$0
Avg Yield on Cost
0.00%

Momentum & MacroiPrice momentum indicators relative to key technical levels: distance from 50-Day SMA (intermediate trend), 200-Day SMA (long-term trend), 52-Week High (bullish proximity), and Beta (market sensitivity coefficient).

vs 50-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
+5.5%
Above/below 50-day moving average
vs 200-Day SMAMoving Averages (SMA)A rolling average of an asset's price over a defined window — used to identify trends and momentum signals.Click for full definition →
-11.9%
Above/below 200-day moving average
vs 52-Week High52-Week HighThe highest price an asset reached in the past 52 weeks — a key reference for momentum and valuation context.Click for full definition →
42.4% from high
Distance from 52-week high
BetaBetaA measure of an asset's sensitivity to broad market movements relative to a benchmark (e.g. S&P 500).Click for full definition →
2.66
Market sensitivity coefficient

Frequently Asked Questions & Methodology

Is Aligos Therapeutics Inc a high-risk investment?

Aligos Therapeutics Inc (ALGS.US) has an annualized volatility of 189.1% and experienced a maximum drawdown of 99.3% over the last 10 years. Its primary macro risk driver is VTI.US.

What is the 10-year return of ALGS.US?

Over the past 10 years, ALGS.US has generated a Compound Annual Growth Rate (CAGR) of -50.7%. It has had a positive return in 17% of the years measured.

Data Methodology & Trust

The risk and return information on this page is pre-calculated mathematically using daily market data spanning a 10-year period. Fundamentals (such as P/E Ratio, Market Cap, and Dividend Yield) represent trailing averages and may not immediately reflect real-time live market fluctuations. Advanced scoring models like the Piotroski F-Score and Altman Z-Score are proxies applied to publicly available trailing-twelve-month financial statements and may not account for recent off-balance-sheet events, qualitative company shifts, or sector-specific capital structures. Macroeconomic factor exposures are estimated via multivariate regression against standard market indices. This data is provided for quantitative insight and backtesting research, and should not be misconstrued as tailored financial advice.

Run a Full Backtest on Aligos Therapeutics Inc

stresstest.pro lets you simulate DCA vs Lump Sum, Monte Carlo projections, portfolio optimisation, and more — all in seconds.

Start a Free Backtest